Possible allergic fungal sinusitis

Annals of Allergy, Asthma & Immunology

April  2016 Volume 116, Pages 290-294  MOC/CME Review


Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for ContinuingMedical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participationin the activity

Planning Committee Members:
Richard D. deShazo, MD (Author)
Jonathan A. Bernstein, MD (CME Subcommittee)
Guha Krishnaswamy, MD (CME Subcommittee)
John J. Oppenheimer, MD (CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
 Discuss recent advances in the diagnosis and treatment of allergic fungal sinusitis
 Discriminate between allergic fungal sinusitis and eosinophilic mucin rhinosinusitis

Additional information
Disclosure: 

M.H. Grayson has received research grants from Children’s Research Institute of the Children’s Hospital of Wisconsin, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, and National Institutes of Health (NIH). G. Krishnaswamy has received research grants from CSL Behring. J. J. Oppenheimer has been a consultant/advisor for GlaxoSmithKline, Meda, Mylan and Teva; has received research grants from AstraZeneca, Bristol-Myers Squibb, Genentech, Novartis, and Sunovion. J.A. Bernstein, R. deShazo, S. Stringer, and L.B. Skipworth have no relevant financial relationships to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
02/01/2016
Course expires: 
01/31/2018
Cost:
$0.00
Richard D. deShazo, MD; Scott Stringer, MD; Leigh Baldwin Skipworth, BA

    Available Credit

    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Attendance
    • 1.00 MOC

    Accreditation Period

    Course opens: 
    02/01/2016
    Course expires: 
    01/31/2018

    Price

    Cost:
    $0.00
    Please login or create an account to take this course.